Literature DB >> 17229238

Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer.

L Fuccio1, R M Zagari, M E Minardi, F Bazzoli.   

Abstract

BACKGROUND: Helicobacter pylori is recognized as one of the most significant risk factors for gastric cancer, and H. pylori eradication has been proposed as a possible primary chemo-preventive strategy to reduce gastric cancer incidence. AIM: To evaluate the available evidence on the efficacy of H. pylori eradication in the prevention of gastric cancer.
METHODS: Epidemiological, observational and interventional studies, as well as decisional models, were taken into account in this review.
RESULTS: Large-scale epidemiological studies clearly link H. pylori infection with non-cardia gastric cancer. Current evidence suggests that, in a subpopulation of treated subjects, H. pylori eradication prevents the progression of preneoplastic lesions. Studies that have attempted to evaluate the effect of H. pylori eradication on the incidence of gastric cancer have not provided definitive answers. H. pylori eradication seems to reduce the incidence of gastric cancer in patients without baseline precancerous gastric lesions. Decisional models suggest that H. pylori screening could be cost-effective, but there is not yet sufficient evidence to support the setting up of a general screening programme.
CONCLUSION: Helicobacter pylori eradication is a plausible intervention for gastric cancer prevention; however, it seems to be relevant in only a subset of subjects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17229238     DOI: 10.1111/j.1365-2036.2006.03183.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  27 in total

1.  Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Joseph Salamoun; Michelle Warthan; Paul S Hoffman; Timothy L Macdonald
Journal:  ChemMedChem       Date:  2010-12-29       Impact factor: 3.466

2.  What are the therapeutic advances in gastroenterology? opinions from world experts.

Authors:  Timothy Cragin Wang; Gordon Mallarkey
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

3.  Does hyperhomocysteinaemia contribute to gastric carcinogenesis in Helicobacter pylori infected patients?

Authors:  L Peyrin-Biroulet; Jean-Louis Guéant
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

4.  Improving outcome for scirrhous gastric cancer.

Authors:  H H Hartgrink
Journal:  Gastric Cancer       Date:  2009       Impact factor: 7.370

Review 5.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

6.  Ethnicity is a strong predictor for Helicobacter pylori infection in young women in a multi-ethnic European city.

Authors:  Wouter J den Hollander; I Lisanne Holster; Caroline M den Hoed; Frances van Deurzen; Anneke J van Vuuren; Vincent W Jaddoe; Albert Hofman; Guillermo I Perez Perez; Martin J Blaser; Henriëtte A Moll; Ernst J Kuipers
Journal:  J Gastroenterol Hepatol       Date:  2013-11       Impact factor: 4.029

Review 7.  Efficacy of Helicobacter pylori eradication for the prevention of metachronous gastric cancer after endoscopic resection for early gastric cancer.

Authors:  Jae Young Jang; Hoon Jai Chun
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

8.  Helicobacter pylori eradication in nonulcer dyspepsia: does it really matter?

Authors:  Ahmad S AlMalki
Journal:  Saudi J Gastroenterol       Date:  2008-04       Impact factor: 2.485

9.  Gastric cancer.

Authors:  Henk H Hartgrink; Edwin P M Jansen; Nicole C T van Grieken; Cornelis J H van de Velde
Journal:  Lancet       Date:  2009-07-20       Impact factor: 79.321

10.  Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice.

Authors:  Katarzyna Leszczyńska; Andrzej Namiot; David E Fein; Qi Wen; Zbigniew Namiot; Paul B Savage; Scott Diamond; Paul A Janmey; Robert Bucki
Journal:  BMC Microbiol       Date:  2009-09-03       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.